Skip to main content

Pharma News


Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • How sensory gamma rhythm stimulation clears amyloid in Alzheimer’s mice

    Studies at MIT and elsewhere are producing mounting evidence that light flickering and sound clicking at the gamma brain rhythm frequency of 40 Hz can reduce Alzheimer’s disease (AD) progression and treat symptoms in human volunteers as well as lab mice.

  • Heart disease research challenges one size fits all aspirin guidelines

    Heart disease researchers have identified a group of patients in whom international guidelines on aspirin use for heart health may not apply.

    In a study published in the renowned medical journal Circulation, the findings of a review of data from three clinical trials challenge current best practice for use of the drug for primary prevention of heart disease or stroke - otherwise known as atherosclerotic cardiovascular disease.  

  • Nicaragua Becomes First Spanish-Speaking Nation to Recognize Indian Pharmacopoeia Standards

    In a significant diplomatic development, Nicaragua has become the first Spanish-speaking nation to officially recognize the Indian Pharmacopoeia (IP) or Indian Pharma standards. This development follows the signing of a Memorandum of Understanding (MoU) on Pharmacopoeia Cooperation between the Governments of India and Nicaragua. The ceremony, held in Nicaragua's capital, saw the signing of the MoU by Dr Sumit Seth, the Indian Ambassador to Nicaragua, and Dr Martha Reyes, Nicaragua's Minister of Health.

  • Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer

    Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy.

  • Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

    Takeda and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs.

  • Roche Pharma launches ocrelizumab in India after six years of global release

    Roche Pharma launches ocrelizumab in India, six years after global release. Ocrelizumab is an FDA-approved CD20-directed humanized monoclonal antibody indicated to treat adult patients with primary progressive or relapsing multiple sclerosis.

  • 100 Rs tablet prevents spread of cancer, breakthrough research by Indian Scientists

    The breakthrough research by TATA memorial centre scientists who have developed a tablet which reduces side effects of cancer treatment and prevent resurgence or relapse of cancer said Dr Rajendra Badwe, Director of the Tata Memorial Centre in an interview with NDTV. The said tablet will be available at an affordable price of Rs. 100 a tablet.

  • Bristol Myers Squibb Completes Acquisition of RayzeBio

    Bristol Myers Squibb announced today that it has successfully completed its acquisition of RayzeBio, Inc. With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.

  • Compounds in female ginseng could lead to new osteoporosis treatments

    With ever-increasing life expectancy comes the challenge of treating age-related disorders such as osteoporosis. Although there are effective drugs for treating this metabolic bone disease, they can be expensive and have side effects, limiting their availability to some people. In the search for alternative drug candidates, researchers reporting in ACS Central Science have discovered and fully replicated a compound from a botanical source, female ginseng, that had potent anti-osteoporotic activity in cellular tests.

  • Drug limits dangerous reactions to allergy-triggering foods : study of kids finds

    A drug can make life safer for children with food allergies by preventing dangerous allergic responses to small quantities of allergy-triggering foods, according to a new study led by scientists at the Stanford School of Medicine. 

    The research was published Feb. 25 in the New England Journal of Medicine. The findings suggest that regular use of the drug, omalizumab, could protect people from severe allergic responses, such as difficulty breathing, if they accidentally eat a small amount of a food they are allergic to.

Subscribe to Pharma News